

Myeloma: diagnosis and management

The Guideline Committee, National Collaborating Centre and NICE project team

Guideline Committee

Sam Ahmedzai

Emeritus Professor, Professor and Head of Palliative Medicine, The University of Sheffield Medical School

Alan Chant

Patient and carer member

Andrea Guy

Clinical Nurse Specialist and Stem Cell Transplant Coordinator, Myeloma and Related Plasma Cell Disorders, St Bartholomews Hospital, London

Matthew Jenner

Consultant Haematologist, University of Southampton NHS Foundation Trust

Nicola Montacute

Palliative Care Clinical Nurse Specialist, Musgrove Park Hospital, Somerset

Curly Morris

Consultant Haematologist, Altnagelvin Hospital, Londonderry

Monica Morris

Clinical Nurse Specialist, St Georges NHS Healthcare Trust, Middlesex

Nicola Mulholland

Consultant Radiologist and Nuclear Medicine Physician; Honorary Senior Lecturer, Kings College Hospital, London.

Guy Pratt

Senior lecturer, Cancer Sciences University of Birmingham and Honorary Consultant Haematologist, Birmingham Heartlands Hospital

Lesley Roberts

Patient and carer member

Hamdi Sati

Consultant Haematologist, Singleton Hospital, ABM University Health Board,
Swansea

John Snowden

Consultant Haematologist, Sheffield Teaching Hospitals NHS Foundation Trust and
Director of Blood and Marrow Transplantation, University of Sheffield

Matthew Streetly

Consultant Haematologist, Guys and St Thomas NHS Foundation Trust, London

Jane Woodward

Patient and carer member

National Collaborating Centre/ Clinical Guideline Centre for Cancer

Angela Bennett

Assistant Centre Manager

Katrina Blears

Project Manager

Nathan Bromham

Senior Researcher

Andrew Champion

Centre Manager

Kimberley Cox

Project Manager

John Graham

Director

Elise Hasler

Information Specialist

James Hawkins

Health Economist

Angharad Morgan

Reviewer

Susan O'Connell

Reviewer

Matthew Prettyjohns

Senior Health Economist

Mia Schmidt-Hansen

Reviewer

Jennifer Stock

Project Manager

NICE project team

Sarah Willett

Guideline Lead

Mark Baker

Clinical Adviser

Katie Perryman Ford

Guideline Commissioning Manager

Thomas Feist

Guideline Coordinator

Steven Barnes

Technical Lead

Ross Maconachie

Health Economist

James Hall

Editor

Laura Sadler

Public Involvement Adviser

Declarations of interests

The following members of the Guideline Committee made declarations of interests. All other members of the Committee stated that they had no interests to declare. The conflicts of interest policy (2007) was followed until September 2014, when an [updated policy](#) was published.

Name	Interest declared	Type of interest	Decision
Curly Morris	Received reimbursement of travel and subsistence expenses, and registration fee to attend the American Society for Haematology Meeting in Atlanta.	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Curly Morris	Received financial support from Celgene to attend the International Myeloma Workshop in Kyoto, Japan. Money was paid to Altnagelvin Haematology Laboratory Trust Funds	Non-personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Curly Morris	Received financial support from Mundi Pharma to attend the European Blood and Marrow Transplant Meeting in London. Money was paid to Altnagelvin Haematology Laboratory Trust Funds	Non-personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Curly Morris	Member of the trial management group and involved in designing the the trial protocol for Myeloma X trial (phase III on the role of a second autologous stem cell transplant in patients with relapsed myeloma following high dose rate chemotherapy and autologous stem cell rescue). Funded by CRUK.	Non-personal pecuniary Specific	Declare and can participate in discussion of all topics as research not funded by the healthcare industry.
Curly Morris	Principal investigator and involved in designing the trial protocol for an Irish Clinical Oncology Research Group (ICORG) sponsored phase II trial of Bortezomib, Adriamycin and Dexamethasone (PAD) in patients with relapsed and refractory myeloma. Costs and free drug from Jansen Cilag.	Non-personal pecuniary Specific	Declare and must withdraw from discussion of any topics which include PAD as an intervention until 12 months after publication of the results
Curly Morris	Received reimbursement of travel expenses from the organisers for speaking on myeloma to	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as

Name	Interest declared	Type of interest	Decision
	data managers at the European Blood and Marrow Transplant meeting		expenses not beyond reasonable amounts
Curly Morris	The Binding Site Ltd have offered to reimburse travel and subsistence expenses for attendance at their conference in Edinburgh.	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as expense not beyond reasonable amounts
Curly Morris	Received reimbursement of travel and subsistence expenses from EMBT for chairing a session and presenting on maintenance and consolidation post transplant in myeloma patients at their conference in Turin	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as expenses not beyond reasonable amounts.
Curly Morris	Has accepted a travel grant from Celgene to attend International Myeloma Workshop in Rome in September.	Personal pecuniary non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable amounts.
Guy Pratt	Receives an annual payment from the Binding Site Ltd for being a member of their advisory board and providing general clinical advice. This involves overseeing, as chief investigator, a study recruiting normal blood donors from within the company for control samples.	Personal pecuniary Specific	Declare and must withdraw from discussion on topics which include interventions made by Binding Site Ltd.
Guy Pratt	Received honorarium from Celgene for chairing a meeting on general myeloma issues.	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as conflict has now expired.
Guy Pratt	Received honorarium from Janssen for a presentation on Waldenstroms.	Personal pecuniary Non-specific	Declare and participate in discussion of all topics as Waldenstroms is not being investigated by the

Name	Interest declared	Type of interest	Decision
			guideline.
Guy Pratt	Received support for travel, accommodation and subsistence expenses from Binding Site Ltd to attend an educational meeting in Japan.	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Guy Pratt	Received support from the Italian Haematology Society to attend and present a lecture on Immunodeficiency in Multiple Myeloma	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Guy Pratt	Chief investigator (and designed trial protocol) for the PICCLE trial (parp inhibitor olaparib in relapsed chronic lymphocytic leukaemia). Astra Zeneca provided free drug support and the trial was supported by Leukaemia Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as chronic lymphocytic leukaemia is not being investigated by the guideline
Guy Pratt	Principal investigator for the PADIMAC trial (Phase II study of bortezomib, adramycin, dexamethasone (PAD) therapy in previously untreated myeloma patients). Funded by Leukaemia Lymphoma Research	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials and not funded by pharmaceutical industry.
Guy Pratt	Principal investigator for the GOYA study (GA-101 +CHOP versus RCHOP chemotherapy in untreated Diffuse Large B-cell NHL). Funded by Roche	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as diffuse large B-cell NHL is not being investigated by the guideline
Guy Pratt	Principal investigator for the Lilly Myeloma trial (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Tabalumab in Combination with Bortezomib and	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.

Name	Interest declared	Type of interest	Decision
	Dexamethasone in relapsed by Myeloma). Funded by Lilly		
Guy Pratt	Principal investigator for the Gilead CLL study (A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia). Funded by Gilead	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as chronic lymphocytic leukaemia is not being investigated by the guideline
Guy Pratt	Co-investigator (involved in designing the trial protocol) for the TEAMM trial (trial assessing the benefit of antibiotic prophylaxis with levofloxacin, and its effect on health care associated infections in patients with newly diagnosed symptomatic myeloma). Funded by NIHR Health Technology Assessment.	Non-personal pecuniary Specific	Declare and can participate in discussion of all topics as research not funded by the healthcare industry.
Guy Pratt	Co-investigator (involved in designing the trial protocol) for the BAP trial (bezafibrate/medroxyprogesteron in chronic lymphocytic leukaemia, acute myeloid leukaemia and non-Hodgkin's lymphoma). Funded by Queen Elizabeth Hospital Trust.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as chronic lymphocytic leukaemia, acute myeloid leukaemia and NHL are not being investigated by the guideline
Guy Pratt	Member of the trial management group for a randomised phase II trial R2W in Waldenström's macroglobulinaemia funded by Cancer Research UK. Involved in trial design, protocol amendments and answering clinical queries.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as Waldenstroms is not being investigated by the guideline
Guy Pratt	Member of the data monitoring committee	Non-personal pecuniary	Declare and participate in

Name	Interest declared	Type of interest	Decision
	(checks safety data) for the LenaRIC trial (Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma). Funded by CTAAC	Specific	discussions on all topics as no supervisory responsibility on trials.
Guy Pratt	Member of the data monitoring committee (checks safety data) for HA-1 trial (A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHA _g) HA-1 using a DNA and MVA 'prime/boost' regimen).	Non-personal pecuniary Non-specific	Declare and participate in discussion on all topics vaccination strategies are not being investigated by the guideline
Guy Pratt	Co-author on an evidence based position statement on bendamustine in multiple myeloma, on behalf of the UK Myeloma Forum and Myeloma UK.	Personal non-pecuniary	Declare and participate in discussion on all topics as conclusions of the paper were based on a review of the published evidence.
Guy Pratt	Co-author on an evidence based position statement on maintenance and consolidation in multiple myeloma, on behalf of the UK Myeloma Forum and Myeloma UK.	Personal non-pecuniary	Declare and participate in discussion on all topics as conclusions of the paper were based on a review of the published evidence and the guideline will not be investigating maintenance and consolidation therapy for myeloma.
Guy Pratt	Registration fee for attendance at the British Society of Haematology Annual Meeting in Birmingham was paid by Janssen.	Personal pecuniary Non-specific	Declare and participate in discussion of topics as payment was no beyond reasonable amounts.
Guy Pratt	Received an honorarium	Personal	Declare and

Name	Interest declared	Type of interest	Decision
	for chairing a medical advisory board for Takeda on ixazomib.	pecuniary Non-specific	participate in discussion of all guideline topics as ixazomib is not being investigated by the guideline.
Guy Pratt	Received an honorarium for chairing a medical advisory board for Amgen on carfilzomib.	Personal pecuniary Specific	Declare and must withdraw from topics which include carfilzomib as an intervention until October 2015
Guy Pratt	Received reimbursement of travel and subsistence expenses from the Binding Site Ltd to attend the American Society of Haematology Conference in San Francisco.	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as payment not beyond reasonable expenses.
Guy Pratt	Received reimbursement of travel and subsistence expenses from The Binding Site Ltd to attend their meeting in Edinburgh.	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as payment not beyond reasonable expenses.
Guy Pratt	Giving a presentation on the management of myeloma for Sebia UK Ltd in Birmingham.	Personal non-pecuniary Non-specific	Declare and participate in discussion of all guideline topics as no payment was received.
Guy Pratt	Received reimbursement for travel and subsistence expenses from Helena Biosciences Europe for giving a talk on international standards for diagnosis and relapse in myeloma in Barcelona	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as payment was not beyond reasonable expenses.
Guy Pratt	Has accepted a travel grant from Takeda to attend the 2015 International Myeloma Workshop in Rome in September	Personal pecuniary non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable amounts.
Guy Pratt	Received a fee in October 2015 from Amgen for speaking on a webinar, giving an update on the	Personal pecuniary non-specific	Declare and can participate in discussions on all topics as

Name	Interest declared	Type of interest	Decision
	IMWG meeting		presentation was not about any specific interventions.
Guy Pratt	Received a fee from Takeda for taking part in a debate on continuous versus fixed term treatment, at an educational meeting in November 2015	Personal pecuniary non-specific	Declare and can participate in discussions on all topics as guideline is not covering treatment of myeloma.
Guy Pratt	Received a travel grant from Binding Site Ltd to attend ASH meeting in December 2015	Personal pecuniary non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable amounts.
Hamdi Sati	Reimbursed for travel expenses to attend the European Haematology Association annual meeting by Napp Pharmaceuticals	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Hamdi Sati	Local principle investigator for the Myeloma X trial (A phase III study to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma following prior high dose chemotherapy and autologous stem cell rescue). Funded by CRUK	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Hamdi Sati	Local principle investigator for the Myeloma XI trial (Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide). Funded by CTAAC	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Hamdi Sati	Local principle investigator for the MM1 trial (investigating whether adding MLN9708 to the	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no

Name	Interest declared	Type of interest	Decision
	combination of lenalidomide and dexamethasone, improves survival in patients with relapsed myeloma). Funded by Millenium Pharmaceuticals.		supervisory responsibility on trials.
Hamdi Sati	Local principle investigator for the PASS observational study (A non-interventional observational post authorisation safety study of subjects treated with lenalidomide). Funded by Celgene	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Hamdi Sati	Local principle investigator for the PREAMBLE observational study (non-interventional observational study aimed at understanding the real world effectiveness of novel agents used in treating multiple myeloma and their impact on patient-reported outcomes). Funded by Bristol Myers Squibb.	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Hamdi Sati	Is a signatory on a myeloma endowment fund (generated by patient donations, no direct contributions from pharmaceutical industry). Used to fund small projects and provide additional resource for ongoing research projects.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as no contributions to the fund from the healthcare industry.
Hamdi Sati	Received reimbursement of travel and subsistence expenses from SHIRE for attending the 19th annual EHA meeting in Milan.	Personal pecuniary Non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable amounts.
Hamdi Sati	Received reimbursement of travel and subsistence expenses from Celgene to attend the European Multiple Myeloma Academy meeting in	Personal pecuniary Non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable

Name	Interest declared	Type of interest	Decision
	Vienna.		amounts
Hamdi Sati	Received reimbursement of travel, subsistence and registration expenses from Bristol-Myers Squibb to attend the American Society of Haematology meeting in San Francisco.	Personal pecuniary Non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable amounts
Hamdi Sati	Is the local principle investigator for a trial examining ixazomib maintenance therapy post Autologous stem cell transplant in newly diagnosed multiple myeloma patients. Trial is sponsored by TAKEDA	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as no supervisory responsibility on trials and the guideline is not covering maintenance therapy.
Hamdi Sati	Received reimbursement of travel and accommodation expenses to attend the 7th international meeting in Edinburgh 16-17 April 2015. Educational sponsorship by Binding site.	Personal pecuniary non-specific	Declare and participate in discussion on all topics as not receiving expenses beyond reasonable amount.
Hamdi Sati	Received an educational grant covering registration, travel and accommodation to attend the EHA 2015 meeting from BMS.	Personal pecuniary non-specific	Declare and participate in discussion on all topics as not receiving expenses beyond reasonable amount.
Hamdi Sati	Local Principal Investigator for Tourmaline C16021 protocol trial examining the role of ixazomib maintenance in transplant ineligible patients, sponsored by Takeda.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as no supervisory responsibility on trials and the guideline is not covering maintenance therapy.
Hamdi Sati	Has accepted a travel grant from Takeda to attend International Myeloma Workshop in Rome in September 2015.	Personal pecuniary non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable

Name	Interest declared	Type of interest	Decision
			amounts.
Hamdi Sati	Received a travel grant from Takeda to attend the American Society of Haematology meeting in December 2015	Personal pecuniary non-specific	Declare and participate in discussion of all topics as expenses not beyond reasonable amounts.
Hamdi Sati	Received an honorarium from Bristol Myers Squibb to give a presentation on chronic myeloid leukaemia in October 2015	Personal pecuniary non-specific	Declare and participate in discussion of all topics as chronic myeloid leukaemia is not being covered by the guideline.
Hamdi Sati	Local PI for the OPTIMISMM trial (Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma). Trial is sponsored by Celgene.	Non-Personal pecuniary non-specific	Declare and participate in discussion of all topics as no supervisory responsibility on trial and the guideline is not covering myeloma treatment.
John Snowden	Received an honorarium from MSD for chairing a meeting on antifungal drugs.	Personal pecuniary Specific	Declare and must withdraw from topics which include antifungal drugs as an intervention until October 2014
John Snowden	Received an honorarium from Celgene for chairing a meeting on myeloma drugs.	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene (thalidomide, lenalidomide and pomalidomide) as an intervention until January 2015
John Snowden	Received an honorarium from MSD for attending an advisory board on Posoconazole	Personal pecuniary Specific	Declare and must withdraw from topics which include posoconazole (antifungal) as an intervention until

Name	Interest declared	Type of interest	Decision
			October 2014
John Snowden	Received reimbursement of accommodation, travel, subsistence and registration fee from MSD, to attend the American Society for Hematology conference in New Orleans	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
John Snowden	Co-applicant on a research grant from Pfizer to investigate characterisation of central brain processing of chemotherapy-induced peripheral neuropathy	Non-personal pecuniary Specific	Declare and must withdraw from topics which include pregablin as an intervention (manufactured by Pfizer for treating peripheral neuropathy). As pharmacological management of neuropathic pain has been excluded from the topic on management of neuropathy, JS can participate in discussion of this topic.
John Snowden	Local principle investigator for the Myeloma XI trial (Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide). Funded by CTAAC	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Local principle investigator for the RIC UCBT trial (Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a reduced intensity conditioning regimen). Funded by The Sue Harris Bone Marrow Trust.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as transplantation of umbilical cord blood is not being investigated by the guideline and has no supervisory responsibility on trials.
John Snowden	Local principle investigator for the MAC UCBT trial	Non-personal pecuniary Non-	Declare and participate in

Name	Interest declared	Type of interest	Decision
	(Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen). Funded by The Sue Harris Bone Marrow Trust.	specific	discussion of all topics as transplantation of umbilical cord blood is not being investigated by the guideline and has no supervisory responsibility on trials.
John Snowden	Local principle investigator for the LenaRIC trial (Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogeneic transplantation for multiple myeloma). Funded by CTAAC.	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Local principle investigator for the ProT-4 trial (Phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for haematological cancers). Funded by Leukaemia and Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as transfer of lymphocytes after transplantation is not being investigated by the guideline and has no supervisory responsibility on trials.
John Snowden	Local principle investigator for the Myeloma IX trial (A randomised trial comparing second generation vs third generation bisphosphonates, induction chemotherapy regimens (CVAD vs CTD, and MP vs CTDa) and thalidomide maintenance vs no maintenance therapy). Funded by MRC	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Local principle investigator for the Myeloma X relapse (intensive) trial (to determine whether a high-dose procedure with autologous transplant is	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on

Name	Interest declared	Type of interest	Decision
	superior to low-dose consolidation therapy following re-induction chemotherapy in patients with relapsed myeloma). Funded by CRUK		trials.
John Snowden	Local principle investigator for the RICAZA trial (Phase II study of the tolerability of adjunctive azacitidine in patients undergoing reduced intensity allogeneic stem cell transplantation for acute myeloid leukaemia). Funded by Celgene.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as transplantation for acute myeloid leukaemia is not being investigated by the guideline and has no supervisory responsibility on trials.
John Snowden	Local principle investigator for the Living with advanced relapsed myeloma study (cross sectional observational study to identify preventable and manageable late effects). Funded by Myeloma UK.	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Local principle investigator for a Phase 2, Multi-centre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma related Bone Disease. Funded by Janssen-Cilag Ltd.	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Local principle investigator for the UK Haplo Trial (A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies). Funded by Leukaemia Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Local principle investigator for the HLA Epitope trial (HLA epitope matched platelet transfusion in aplastic anaemia, MDS	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as aplastic anaemia,

Name	Interest declared	Type of interest	Decision
	and AML patients) Funded by NHS Blood and Transplant (NHSBT)		myelodysplastic syndrome and acute myeloid leukaemia are not being investigated by the guideline and no supervisory responsibility on trials.
John Snowden	Principle investigator of a charitable grant from Royal Hallamshire Hospital Leukaemia and Research Fund, for a bolt-on study to Myeloma X, relating to supportive care in myeloma.	Non-personal pecuniary Specific	Declare and can participate in discussion of all topics as research not funded by the healthcare industry.
John Snowden	Co-investigator on the MUK5 trial (A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma). Funded by Myeloma UK	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Co-investigator on the TEAMM trial (trial assessing the benefit of antibiotic prophylaxis with levofloxacin, and its effect on health care associated infections in patients with newly diagnosed symptomatic myeloma). Funded by NIHR Health Technology Assessment.	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Co-investigator on the AML 17 trial (Working parties on leukaemia in adults and children trial in AML or high risk MDS 17). Funded by CRUK	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as leukaemia, AML and MDS are not being investigated by the guideline no supervisory responsibility on trial.

Name	Interest declared	Type of interest	Decision
John Snowden	Co-investigator on the FiTT study (Investigating the effectiveness of co-morbidity assessment in male patients with myeloma and prostate cancer). Funded by Weston Park Hospital Cancer Charity and Sheffield Teaching Hospitals NHS Foundation trust.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Co-investigator on the AML 15 trial (Working parties on leukaemia in adults and children AML trial 15). Funded by MRC.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as leukaemia is not being investigated by the guideline no supervisory responsibility on trial.
John Snowden	Co-investigator on the AML 16 trial (A programme of development for older patients with AML and high risk MDS). Funded by CRUK.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as AML and MDS are not being investigated by the guideline no supervisory responsibility on trial.
John Snowden	Co-investigator on the MCL MiniAllo trial (Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma). Funded by CRUK, Genzyme Therapeutics, National Institute for Health Research Cancer Network (NRCN).	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as mantle cell lymphoma is not being investigated by the guideline no supervisory responsibility on trial.
John Snowden	Co-investigator on the ORCHARRD trial (Ofatumumab rituximab chemoimmunotherapy ASCT relapsed refractory DLBCL). Funded by GlaxoSmithKline.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as diffuse large B cell lymphoma is not being investigated by the guideline no supervisory

Name	Interest declared	Type of interest	Decision
			responsibility on trial.
John Snowden	Co-investigator on the FIGARO trial (A randomised trial of the FLAMSA-BU conditioning regimen in patients with AML and MDS undergoing allogeneic stem cell transplantation). Funded by Leukaemia and Lymphoma Research.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as AML and MDS are not being investigated by the guideline no supervisory responsibility on trial.
John Snowden	Co-investigator on the MUK 4 trial (phase II trial of combination treatment with Vorinostat, bortezomib and dexamethasone in patients with relapsed multiple myeloma). Funded by Myeloma UK	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Co-investigator on the SarCaBon trial (A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain). Funded by MRC	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
John Snowden	Member of the UK Myeloma Forum. Involved in writing the evidence-based position statement: 'The use of consolidation and maintenance treatment in myeloma'	Personal non-pecuniary Non-specific	Declare and participate in discussion on all topics as conclusions of the paper were based on a review of the published evidence and the guideline will not be investigating maintenance and consolidation therapy for myeloma.
John Snowden	Member of the UK Myeloma Forum has been involved in writing the evidence-based position statement: 'The use of bendamustine in myeloma'	Personal non-pecuniary	Declare and participate in discussion on all topics as conclusions of the paper were based on a review of the published evidence.

Name	Interest declared	Type of interest	Decision
John Snowden	Executive member of the UK Myeloma Forum, a non-profit organisation for the support of UK health professionals and scientists in the myeloma field.	Personal non-pecuniary	Declare and participate in discussion on all topics as interest does not impact on content of the guideline.
John Snowden	Co-author on the following abstract, which were prepared by BresMed on behalf of Celgene: Stradwick S, Freemantle N, Snowden J, Rodrigues F, Brereton N. 2012. Comparative Effectiveness of Lenalidomide plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison. Blood (ASH Annual Meeting Abstracts); 120 (21): A4076.	Personal non-pecuniary	Declare and must withdraw from discussion of any topics which include drugs manufactured by Celgene as interventions (pomalidomide, thalidomide, lenalidomide) until November 2013
John Snowden	Co-author on the following abstract, which were prepared by BresMed on behalf of Celgene: Stradwick S, Freemantle N, Vickers A, Rodrigues F, Monzini M, Brereton N, Snowden. 2013. Comparative Effectiveness of Lenalidomide Plus Dexamethasone Versus Bortezomib Subcutaneous for the Treatment of RRMM. Presented at the 14th International Myeloma Workshop (IMW); Kyoto, Japan; April 3–7.	Personal non-pecuniary	Declare and must withdraw from discussion of any topics which include drugs manufactured by Celgene as interventions (pomalidomide, thalidomide, lenalidomide) until April 2014
John Snowden	Received reimbursement of travel expenses from the organisers for speaking on quality in transplantation at the Joint Accreditation Committee in Autoimmune Diseases meeting	Personal pecuniary Non-specific	Declare and participate in discussion on all guideline topics as expenses not beyond reasonable amounts.

Name	Interest declared	Type of interest	Decision
John Snowden	Will receive an honorarium for from Sanofi for attending an advisory board on the mobilising agent plerixafor and possibly some future currently unlicensed drugs	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as plerixafor is not being investigated by the guideline.
Matthew Jenner	Received an honorarium from Napp Pharmaceuticals for attending an advisory board on bendamustine.	Personal pecuniary Specific	Declare and must withdraw from any topics which include bendamustine as an intervention until December 2014
Matthew Jenner	Received payment from Janssen for giving an interview on the delivery of bortezomib in the community setting	Personal pecuniary Specific	Declare and must withdraw from any topics which include bortezomib as an intervention until December 2014
Matthew Jenner	Received payment from Celgene for chairing a debate on drug treatment of relapsed myeloma.	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene (thalidomide, lenalidomide and pomalidomide) as an intervention until November 2014.
Matthew Jenner	Received reimbursement of travel and subsistence from Napp Pharmaceuticals to attend the American Society of Haematology meeting in New Orleans	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Matthew Jenner	Received reimbursement of travel and subsistence from Janssen to attend the International Myeloma Workshop in Japan	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Matthew Jenner	Has been offered reimbursement of travel and subsistence expenses from Celgene to attend the European Haematology	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond

Name	Interest declared	Type of interest	Decision
	Association		reasonable amounts.
Matthew Jenner	Is local principle investigator for the MM1 trial (investigating the effect of adding MLN9708 to the combination of lenalidomide and dexamethasone, improves survival in patients with relapsed myeloma). Funded by Millenium Pharmaceuticals.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Jenner	Is local principle investigator for the FOCUS trial (Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma). Funded by Onyx Pharmaceuticals	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Jenner	Is local principle investigator for the MUK five trial (phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma). Funded by Myeloma UK	Non-personal pecuniary	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Jenner	Is local principle investigator for the MUK four trial (Phase II Trial of combination treatment with Vorinostat, Bortezomib and Dexamethasone in participants with Relapsed Multiple Myeloma). Funded by Myeloma UK.	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Jenner	Is local principle investigator for the Myeloma IX trial (randomised trial comparing second	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory

Name	Interest declared	Type of interest	Decision
	generation vs third generation bisphosphonates, induction chemotherapy regimens (CVAD vs CTD, and MP vs CTDa) and thalidomide maintenance vs no maintenance therapy). Funded by the Medical Research Council.		responsibility on trials.
Matthew Jenner	Is local principle investigator for the Myeloma X trial (phase III on the role of a second autologous stem cell transplant in patients with relapsed myeloma following high dose rate chemotherapy and autologous stem cell rescue). Funded by Cancer Research UK	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Jenner	Is local principle investigator for the Myeloma XI trial (Randomised comparisons in myeloma patients of all ages of thalidomide, lenalidomide and bortezomib combinations and maintenance lenalidomide). Funded by CTAAC	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Jenner	Signatory for a charitable hospital fund used for education and development for healthcare professionals. No contribution to this fund from the pharmaceutical industry.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as no contributions to the fund from the healthcare industry.
Matthew Jenner	Was part of the group who developed evidence based guidelines on myeloma for the BCSH.	Personal non-pecuniary	Declare and participate in discussion on all topics as interest does not impact on content of the guideline.

Name	Interest declared	Type of interest	Decision
Matthew Jenner	Is chief investigator for the MUK four trial investigating bortezomib and dexamethasone with vorinostat in relapsed myeloma. Involved in designing the trial protocol. The trial is funded by Myeloma UK.	Non-personal pecuniary Specific	Declare and participate in discussion of all guideline topics as the trial is not funded by the pharmaceutical industry
Matthew Jenner	Is local PI for the Pollux study. A randomised phase III study investigating lenalidomide and dexamethasone +/- daratumumab in relapsed myeloma. The study is funded by Janssen.	Non-personal pecuniary	Declare and participate in discussion of all guideline topics as not involved in designing the trial protocol and no supervisory responsibility for trial
Matthew Jenner	Received reimbursement of travel and subsistence expenses and an honorarium from Amgen Oncology for taking part in an advisory board on carfilzomib.	Personal pecuniary Specific	Declare and withdraw from discussion of topics that include carfilzomib as an intervention until September 2015. Chairpersons action that can be asked questions on the evidence base but must not participate in drafting recommendations
Matthew Jenner	Received reimbursement of travel and subsistence expenses and an honorarium from Takeda UK for participating in an advisory board on myeloma	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as interventions manufactured by Takeda are not being investigated by the guideline
Matthew Jenner	Invited to present on cytogenetics at an educational symposium at the British Society of Haematology Annual Scientific Meeting. MJ will only receive reimbursement of travel expenses	Personal pecuniary Non-specific	Declare and participate in discussion on all topics as not receiving expenses beyond reasonable amount

Name	Interest declared	Type of interest	Decision
Matthew Jenner	Member of the Myeloma XI trial management group. Myeloma X1 trial is investigating different chemotherapy schedules in newly diagnosed myeloma. These include schedules containing different combinations including thalidomide, lenalidomide, bortezomib and carfilzomib. The trial is primarily funded through CTAAC (Cancer Research UK). Sponsor is University of Leeds.	Non-personal pecuniary Specific	Declare and participate in all discussion as research not funded by the healthcare industry
Matthew Jenner	Received economy class travel, accommodation and registration for the European Haematology Association Annual Meeting in Vienna, 11-14 June 2015 by Janssen.	Personal pecuniary non-specific	Declare and participate in discussion on all topics as not receiving expenses beyond reasonable amount.
Matthew Jenner	Local principle investigator for the CENTAURUS study (a Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma). Sponsored by Janssen.	Non-personal pecuniary non-specific	Declare and participate in discussion on all topics as no supervisory responsibility for the trial and daratumumab is not being investigated by the guideline.
Matthew Jenner	Local principle investigator for the MAIA study (phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy)	Non-personal pecuniary specific	Declare and participate in discussion on all topics as no supervisory responsibility for the trial.
Matthew Jenner	Local principle investigator for the OPTIMISSM trial (phase 3, multicentre, randomized, open label study to compare the	Non-personal pecuniary non-specific	Declare and participate in discussion of all topics as no supervisory

Name	Interest declared	Type of interest	Decision
	efficacy and safety of pomalidomide, bortezomib and low-dose dexamethasone versus bortezomib and lose-dose dexamethasone in subjects with relapsed or refractory multiple myeloma)		responsibility on trial and the guideline is not covering myeloma treatment.
Matthew Jenner	Local principal investigator for the ACE-MY-01 study (a phase 1b study of ACP-196 in subjects with multiple myeloma). Sponsored by Acerta Pharma.	Non-personal pecuniary non-specific	Declare and can participate in discussion of all topics as no supervisory responsibility on the trial and BTK inhibitors are not being investigated by the guideline.
Matthew Jenner	Local principal investigator for NEOD001-CL002 trial (Phase 3, Randomized, Multicenter, DoubleBlind, PlaceboControlled, 2 Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis. Sponsored by Acerta Pharma	Non-personal pecuniary non-specific	Declare and can participate in discussion of all topics as no supervisory responsibility on the trial and guideline is not covering light chain amyloidosis.
Matthew Jenner	Local principal investigator for MUK eight trial (randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenolidomide and bortezomib).	Non-personal pecuniary non-specific	Declare and participate in discussion of all topics as no supervisory responsibility on trial and the guideline is not covering myeloma treatment.
Matthew Jenner	Has accepted sponsorship from Takeda/Millennium Pharmaceuticals to attend the European Hematology Association Annual meeting in Copenhagen in June 2016.	Personal pecuniary non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.

Name	Interest declared	Type of interest	Decision
Matthew Streetly	Received payment from Celgene for attending an advisory board on lenalidomide usage in myeloma	Personal pecuniary Specific	Declare and must withdraw from any topics which include lenalidomide as an intervention until June 2014.
Matthew Streetly	Received reimbursement of travel and subsistence expenses from Janssen, for attending the International Myeloma Workshop	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Matthew Streetly	Received payment from Celgene for giving a presentation on "Optimising Myeloma therapy"	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene (thalidomide, lenalidomide and pomalidomide) as an intervention until November 2014.
Matthew Streetly	Received payment from Celgene for giving presentations on "Pomalidomide Case Histories"	Personal pecuniary Non-specific	Declare and must withdraw from any topics which include pomalidomide as an intervention until November 2014.
Matthew Streetly	Received payment from Janssen for giving a presentation on "Transplant: what is the data telling us?". Provided data on induction chemotherapy prior to transplant.	Personal pecuniary Specific	Declare and must withdraw from any topics which include induction chemotherapy as an intervention until October 2014. Induction chemotherapy is not being investigated by the guideline as there is a NICE Technology Appraisal in development in this area. Therefore MS will be able to participate in

Name	Interest declared	Type of interest	Decision
			discussion of all topics
Matthew Streetly	Received payment from Celgene for giving a presentation on "Pomalidomide Background: Summary of Recent Data"	Personal pecuniary Non-specific	Declare and must withdraw from any topics which include pomalidomide as an intervention until September 2014.
Matthew Streetly	Received payment from Janssen for giving a presentation on "Managing Patient's Expectations"	Personal pecuniary Non-specific	Declare and participate in discussion of all topics as subject of presentation is not specific to the content of the guideline.
Matthew Streetly	Received payment from Celgene for giving a presentation on "Myeloma treatment in South East London"	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene (thalidomide, lenalidomide and pomalidomide) as an intervention until February 2014.
Matthew Streetly	Had a consultative role on the Burden of Relapse study (a non-treatment related clinical study examining the impact (physical, psychological, economic) of periods of remission in comparison to periods of disease activity). Received payment from Celgene for teleconference participation every few months and review of data	Personal pecuniary Specific	Declare and must withdraw from topics which include myeloma drugs manufactured by Celgene (thalidomide, lenalidomide and pomalidomide) as an intervention until January 2015.
Matthew Streetly	Chief investigator of the MM013 study (Phase 2 multicentre, open-label study to determine the efficacy and safety of pomalidomide in combination with low dose dexamethasone in subjects with relapsed or	Non-personal pecuniary Non-specific	Declare and must withdraw from topics which include pomalidomide as an intervention. Chair persons action that can be asked questions on

Name	Interest declared	Type of interest	Decision
	refractory myeloma). Trial funded by Celgene. Not involved in designing the trial protocol.		the evidence base but must not be involved in drafting recommendations.
Matthew Streetly	Local principle investigator for the PADIMAC study (Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT). Funded by Leukaemia & Lymphoma Research	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Streetly	Local principle investigator for the TEAMM trial (trial assessing the benefit of antibiotic prophylaxis with levofloxacin, and its effect on health care associated infections in patients with newly diagnosed symptomatic myeloma). Funded by NIHR Health Technology Assessment.	Non-personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Streetly	Local principle investigator for the CLARION trial (Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma). Funded by Onyx Therapeutics	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Streetly	Local principle investigator for the CNTO328 trial (Siltuximab (compared with placebo) in Patients With High-risk Smoldering Multiple Myeloma). Funded by Janssen	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Streetly	Local principle investigator for the PASS observational study (A	Non-personal pecuniary Specific	Declare and participate in discussions on all

Name	Interest declared	Type of interest	Decision
	non-interventional observational post authorisation safety study of subjects treated with lenalidomide). Funded by Celgene		topics as no supervisory responsibility on trials.
Matthew Streetly	Principle investigator for phase III trial in relapsed myeloma (patients randomised between daratumumab with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone). Trial is funded by Janssen	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Matthew Streetly	Written a position statement for the UK Myeloma Forum, about horizon scanning for new agents in myeloma. Statement does not advocate any particular agents.	Personal non-pecuniary	Declare and participate in discussion on all topics as interest does not impact on content of the guideline.
Matthew Streetly	Planning to write a review of the long-term follow up data for a trial on pomalidomide.	Personal non-pecuniary	Declare and must withdraw from topics which include pomalidomide as an intervention. Chair persons action that can be asked questions on the evidence base but must not be involved in drafting recommendations.
Matthew Streetly	Was sponsored to attend the American Society of Haematology Meeting in San Francisco by Janssen. Sponsorship covers flights accommodation and conference registration.	Personal pecuniary Non-specific	Declare and participate in discussion on all topics as sponsorship is not beyond reasonable amounts.
Matthew Streetly	Accepted a travel award from Janssen Pharmaceuticals to attend the International Myeloma workshop in Rome in September 2015	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.

Name	Interest declared	Type of interest	Decision
Matthew Streetly	Received travel, conference registration and hotel support from Janssen-Cilag to attend the American Society of Haematology meeting in December 2015.	Personal pecuniary Non-specific	Declare and can participate in discussion of all topics as expenses not beyond reasonable amounts.
Matthew Streetly	Local principal investigator for the ACE-MY-01 study (a phase 1b study of ACP-196 in subjects with multiple myeloma). Sponsored by Acerta Pharma.	Non-personal pecuniary non-specific	Declare and can participate in discussion of all topics as no supervisory responsibility on the trial and BTK inhibitors are not being investigated by the guideline.
Sam Ahmedzai	An honorarium from MSD was paid to his department for giving a lecture on 'The Science of Symptoms'	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as subject of presentation is not specific to the content of the guideline.
Sam Ahmedzai	An honorarium from Creative Ceutical was paid to his department for taking part in a teleconference to set up an interview study of quality of life in advanced breast cancer	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as advanced breast cancer is not being investigated by the guideline.
Sam Ahmedzai	An honorarium from Amgen was paid to his department for giving a lecture on metastatic bone disease.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as metastatic bone disease is not being investigated by the guideline.
Sam Ahmedzai	An honorarium from Napp Pharmaceuticals was paid to his department for taking part in an advisory board on pain.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as management of pain is not being investigated by the guideline.
Sam Ahmedzai	An honorarium from Prostrakan was paid to his department for giving a	Non-personal pecuniary Non-	Declare and participate in discussion of all

Name	Interest declared	Type of interest	Decision
	lecture on introduction to nausea and vomiting and its management	specific	topics as management of nausea and vomiting is not being investigated by the guideline.
Sam Ahmedzai	An honorarium from Archimedes was paid to his department for participating in the Archimedes Academy. Participation includes chairing the meeting and helping to select topics and speakers. Also gave a lecture on 'Update on pain control', and took part in a debate on end of life care.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as subject of presentation is not specific to the content of the guideline.
Sam Ahmedzai	An honorarium from the World Association for Sleep Medicine was paid to his department for participating in their symposium	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as subject of presentation is not specific to the content of the guideline.
Sam Ahmedzai	An honorarium from Gruenthal was paid to his department for participating in an advisory board on education and awareness strategies for breakthrough cancer pain	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as breakthrough cancer pain is not being investigated by the guideline.
Sam Ahmedzai	An honorarium from Bayer was paid to his department for taking part in a meeting on Sativex	Non-personal pecuniary Specific	Declare and can participate in discussion of all topics as pharmacological management of neuropathic pain has been excluded from the topic on management of neuropathy.
Sam Ahmedzai	Chief investigator a study to investigate characterisation of central brain processing of chemotherapy-induced peripheral neuropathy.	Non-personal pecuniary Specific	Declare and must withdraw from topics which include pregablin as an intervention (manufactured by

Name	Interest declared	Type of interest	Decision
	Funded by Pfizer		Pfizer for treating peripheral neuropathy). As pharmacological management of neuropathic pain has been excluded from the topic on management of neuropathy, SA can participate in discussion of this topic
Sam Ahmedzai	Chief investigator for an observational study looking at a new treatment for opioid-induced constipation in cancer patients. Study is funded by Astra Zeneca.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as management of opioid induced constipation is not being investigated by the guideline.
Sam Ahmedzai	Chief investigator for a study of an experimental new opioid for pain control in cancer patients. Study is funded by Grunenthal	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as pain control is not being investigated by the guideline.
Sam Ahmedzai	Chief investigator for a study on a pain killer for cancer and non-cancer patients. Study is funded by Mundi Pharma	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as pain control is not being investigated by the guideline.
Sam Ahmedzai	Chief investigator for a study to measure the response to 'Standard laxative treatment' (SLT) in patients with opioid-induced constipation, across several European countries. Study is funded by Mundi Pharma.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as management of opioid induced constipation is not being investigated by the guideline.
Sam Ahmedzai	Chief investigator for a study to investigate HRQOL of triple negative breast cancer patients. Funded by Creative Ceutical	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as breast cancer is not being investigated by the guideline.

Name	Interest declared	Type of interest	Decision
Sam Ahmedzai	Is co-investigator of a trial of an experimental drug to treat bone cancer pain in cancer patients. Trial is funded by the MRC and Astra Zeneca.	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as pain control is not being investigated by the guideline and no supervisory responsibility on trials.
Sam Ahmedzai	Fund holder for the SPORG research group. Money is spent on supportive and palliative care research. No contributions to the fund from pharmaceutical companies	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as no contributions to the fund from the healthcare industry.
Sam Ahmedzai	Received an honorarium and reimbursement of travel expenses from Mundipharma for lectures given during the Pain Forum lecture tour in South East Asia and Brazil on: <ul style="list-style-type: none"> • 'pain in special populations' • 'assessing and treating pain in patients with substance abuse concerns' • case presentations on cancer pain, palliative care, neuropathic pain and non-malignant pain. • adequacy of opioid analgesic consumption at country, global and regional levels. 	Personal pecuniary Specific	Declare and must withdraw from topics which include analgesics as interventions (Mundipharma make analgesics) until April 2015.
Sam Ahmedzai	Received reimbursement of travel and subsistence expenses to attend the European Hyponatraemia Network conference in Zurich from Otsuka	Personal pecuniary Non-specific	Declare and participate in discussion of all topics as payment was not beyond reasonable amounts.
Sam	Gave a lecture on 'issues	Non-personal	Declare and

Name	Interest declared	Type of interest	Decision
Ahmedzai	associated with therapeutic opioids - – an evidence-based approach to pain management' at the World Institute of Pain in Maastricht. Travel and subsistence expenses were reimbursed by Mundipharma for attending and an honorarium from Mundipharma was paid to the University of Sheffield	pecuniary Non-specific	participate in discussion of all topics as payment was not beyond reasonable amounts and pain management is not being investigated by the guideline.
Sam Ahmedzai	Meeting with Chugai to discuss potential research into weight loss in cancer in collaboration with NCRI.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as weight loss as a symptom is not being covered by the guideline and the research is not funded by the healthcare industry.
Sam Ahmedzai	Had a meeting with Chugai, in his capacity as chair of the NCRI studies group, to discuss a potential study on weight loss in cancer.	Non-personal pecuniary Non-specific	Declare and participate in discussion on all topics as weight loss as a symptom is not being covered by the guideline and the research is not funded by the healthcare industry.
Sam Ahmedzai	Appointed (January 2015) by Royal College of Physicians to be their Clinical Lead for the National Care of the Dying Audit. Funded post (1 PA per week) that will be paid direct to SA. Role is to advise and lead the RCP audit team in designing a new format for the National Care of the Dying Audit, overseeing its application and helping RCP to announce and	Personal pecuniary Non-specific	Declare and participate in discussion on all topics as not specific to myeloma.

Name	Interest declared	Type of interest	Decision
	disseminate the results.		
Nicola Mulholland	Principle investigator for a trial on biomarkers in lymphoma. Involved in designing the trial protocol. Funded by The Elimination of Leukaemia Fund.	Non-personal pecuniary Non-specific	Declare and participate in discussion of all topics as lymphoma is not being covered by the guideline and the research is not funded by the healthcare industry.
Nicola Mulholland	Sub-investigator for the ZEST study (Zevalin for older people with diffuse large B cell lymphoma). Funded by Spectrum Pharmaceuticals. Involvement is to administer the drug – not involved in collecting or analysing the data	Non-personal pecuniary Non-specific	Declare and participate in discussions on all topics as diffuse large B cell lymphoma is not being investigated by the guideline and no supervisory responsibility on trial.
Nicola Mulholland	Investigator on a phase I/II study of ¹⁷⁷ Lu-HH1 (Betalutin™) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin's Lymphoma. Funded by Nordic Nanovector AS	Non-personal pecuniary Non-specific	Declare and participate in discussion on all topics as non-Hodgkin Lymphoma is not being investigated by the guideline
Nicola Mulholland	Investigator on the NETTER-1 clinical trial. A phase III trial study comparing treatment with ¹⁷⁷ LU-DOTA0-Tyr3-Oscitrotate to Octreotate LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors. Trial funded by Advanced Accelerator Applications.	Non-personal pecuniary Non-specific	Declare and participate in discussion on all topics as midgut carcinoid tumours are not being investigated by the guideline.
Nicola Mulholland	Investigator on the Foxfire study. An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- interventional radio-embolisation as first line treatment for patients	Non-personal pecuniary Non-specific	Declare and participate in discussion on all topics as colorectal cancer is not being investigated by the guideline.

Name	Interest declared	Type of interest	Decision
	with unresectable liver-only or liver-predominant metastatic colorectal cancer		
Nicola Mulholland	In the process of applying for an ARSAC licence to be an investigator on a phase III, randomised placebo controlled, double blind study of oral ixazomib citrate (MLN9708) maintenance therapy in patients with multiple myeloma following autologous stem cell transplant. Funded by Millenium Pharmaceuticals	Non-personal pecuniary Non-specific	Declare and participate in discussion on all topics as maintenance therapy is not being investigated by the guideline.
Nicola Mulholland	Received an honorarium and reimbursement for travel and subsistence expenses from Sirtex for attending their quest investigator study in Sweden	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as Sirtex manufacture interventions for the treatment of liver cancer which is not being investigated by the guideline
Nicola Mulholland	Received reimbursement of travel and subsistence expenses from TheraSphere for attending their training session in Germany	Personal pecuniary Non-specific	Declare and participate in discussion of all guideline topics as expenses not beyond reasonable amounts and TheraSphere manufacture interventions for the treatment of liver cancer which is not being investigated by the guideline.
Nicola Mulholland	Has been sponsored to undertake a study on lymphoma.	Non-personal pecuniary Non-specific	Declare and participate in discussion on all topics as topic not covered in the guideline.
Andrea Guy	Attended a symposium on pomalidomide organised by Celgene. No fee	Personal non-pecuniary	Declare and participate in discussion of all

Name	Interest declared	Type of interest	Decision
	received. Symposium was to present the data on this drug		topics as no fee received.
Andrea Guy	Local principle investigator on myeloma lifestyle study on the management of fatigue. Trial is funded by Cancer Research UK. Celgene have funded a physiotherapist's salary to work on the trial.	Non personal pecuniary Specific	Declare and participate in discussions on all topics as no supervisory responsibility on trials.
Andrea Guy	Attended the European Multiple Myeloma Academy educational meeting in Vienna. Travel expenses paid by event organisers.	Personal pecuniary Non specific	Declare and participate in discussion of all guideline topics as payment was not beyond reasonable amounts.
Monica Morris	Received honorarium for attending a nurse educational event held by Janssen on the supportive care needs of patients with myeloma.	Personal pecuniary Specific	Declare and must withdraw from any topics which involve the supportive needs of patients until May 2014.
Monica Morris	Provided advice for Janssen on the content of a nurse educational leaflet on the management of patients on Bortezomib. No payment was received.	Personal non-pecuniary Specific	Declare and participate in discussion of all guideline topics as no payment was received and a colleague is to take over the work for the duration of the guideline.
Monica Morris	Planning to publish the findings of her MSc research into the experience of myeloma family carers. No financial support was provided for the research.	Personal non-pecuniary Specific	Declare and participate in discussion of all guideline topics as no payment was received.
Monica Morris	Has been invited to take part in an advisory group for Myeloma UK looking at their research strategy. Travel and subsistence expenses will be paid by Myeloma UK. No honorarium or other payment will be received.	Personal pecuniary Non specific	Declare and participate in discussion of all guideline topics as payment is not beyond reasonable amounts.

Name	Interest declared	Type of interest	Decision
Monica Morris	Received reimbursement of travel and subsistence expenses from Celgene for attending the Myeloma Academy educational event in Vienna	Personal pecuniary Non specific	Declare and participate in discussion of all guideline topics as payment is not beyond reasonable amounts.
Monica Morris	Received an honorarium from Novartis for attending a nursing advisory board meeting on Panobinostat	Personal pecuniary Non specific	Declare and participate in discussion of all guideline topics as panobinostat is not being investigated by the guideline.
Monica Morris	Acts as a reviewer for the myeloma section of the Cancer Research UK patient information website (CancerHelp UK). This review is done every 2 years. Receives a small payment from CRUK.	Personal Pecuniary Non-specific	Declare and participate in discussion of all topics as review is on myeloma in general and it is not funded from the healthcare industry.